eTherapeutics

e-Therapeutics is a UK-based company specializing in drug discovery and development. It leverages computational biology to expedite the drug discovery process, particularly in RNA interference (RNAi) medicines. The company's approach integrates network analysis, machine learning, AI, data mining, and optimization into its proprietary databases and computational tools to identify and develop therapies. 

The company utilizes two platforms: 1) The HepNet Computational Platform, which is an in-silico (performed via computer simulation) laboratory that allows users to conduct hypotheses, phenotypic screening, and the identification and prioritization of novel therapeutic targets, and 2) the GalOmic RNAi Platform that enables highly specific silencing of gene expression and specializes in the development of RNAi therapies.

Further, it has four drug candidates in the pipeline, namely 1) ETX-312 to treat metabolic dysfunction-associated steatohepatitis (MASH), 2) ETX-407 to treat dry age-related macular degeneration (dAMD), 3) ETX-148 to treat pan-haemophilia, and 4) ETX-291 to treat a broad spectrum of cardiometabolic diseases.

Key customers and partnerships

The company’s customers include several pharmaceutical companies to develop therapies using its proprietary platforms. These include partnerships with Novo Nordisk (December 2018), Galapagos (June 2020), and iTeos Therapeutics (April 2022). It is also working with another undisclosed top-five pharma company in a specific area of neurodegeneration. 

Further in May 2018, the company partnered with C4X Discovery to identify new pathophysiological mechanisms in Parkinson’s disease. 

Funding and financials

In 2007, the company was listed on the Alternative Investment Market, the London Stock Exchange’s public market for small and medium-sized growth companies, under the ticker symbol “ETX”. Further in September 2022 , the company raised GBP 13.5 million (USD 15.1 million) from funds managed by institutional investor M&G Investment Management Limited via the subscription of new ordinary shares. The funds were expected to be used for the company's growth initiatives.